AR and pachyonychia congenita: Multiple clinical studies have linked AR-V7 expression in PC cells to the resistance to AR antagonists, such as enzalutamide, and disease progression, and non-invasive assays to detect this splice variant in circulating tumor cells may indicate whether individual PC patients are likely to respond to these drugs or progress quickly [108,109].